Filing Flows › Eton Pharmaceuticals (ETON) › Q2 2026 › vs Q2 2025
Eton Pharmaceuticals (ETON) Q2 2026 vs Q2 2025 (year over year)
Eton Pharmaceuticals's revenue rose $18.7M (+99%) from $18.9M in Q2 2025 to $37.6M in Q2 2026. Gross margin 67.6% against 63.0% (+4.6 pts).
Eton Pharmaceuticals, Q2 2026: revenue $37.6M (+99% year over year), operating margin 34.0%, net earnings $11.6M, operating cash flow $7.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 67.6% | 63.0% | +4.6 pts |
| Operating margin | 34.0% | -7.8% | +41.8 pts |
| Net margin | 30.8% | -13.7% | +44.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $37.6M | $18.9M | $18.7M | +99% |
| Gross profit | $25.4M | $11.9M | $13.5M | +113% |
| Cost of revenue | $12.2M | $7.0M | $5.2M | +74% |
| Operating profit | $12.8M | −$1.5M | $14.3M | — |
| Operating expenses | $12.6M | $13.4M | −$780K | -6% |
| Pre-tax earnings | $11.7M | −$2.5M | $14.2M | — |
| Other expense, net | $1.1M | $1.0M | $32K | +3% |
| Research & development | $993K | $3.7M | −$2.7M | -73% |
| General & admin | $11.6M | $9.7M | $1.9M | +20% |
| Net earnings | $11.6M | −$2.6M | $14.2M | — |
| Income tax | $140K | $66K | $74K | +112% |
| Depreciation & amortization | $1.4M | $1.0M | $381K | +38% |
| Share-based compensation | $1.5M | $2.1M | −$628K | -30% |
| Working capital & other | $7.2M | −$7.4M | $14.6M | — |
| Operating cash flow | $7.3M | $8.0M | −$704K | -9% |
Questions
How much did Eton Pharmaceuticals's revenue grow year over year in Q2 2026?
Eton Pharmaceuticals's revenue rose $18.7M (+99%) from $18.9M in Q2 2025 to $37.6M in Q2 2026. Gross margin 67.6% against 63.0% (+4.6 pts).